CORPORATE EVENTS

MEMO # 09-449 DATE: 10/15/09

ACTION: On July 20, 2009, Shareholders of Wyeth ("WYE") voted

concerning the proposed merger with Pfizer Inc. ("PFE").

The merger was approved and subsequently

consummated on October 15, 2009. As a result, each existing WYE Common Share will be converted into the right to receive .985 PFE Common Shares and \$33.00 Cash. Cash will be paid in lieu of fractional PFE shares.

This action will be coordinated with the Options Clearing

Corporation.

CATEGORY: Merger

EQUITY SYMBOL: Wyeth ("WYE")

ONE CHICAGO SYMBOL: WYE1C will change to WYE2C; WYE1C will not be

reintroduced

CME FUTURES SYMBOL: WY will change to WY8

MULTIPLIER: 100 (e.g., 1.00 equals \$100.00)

EFFECTIVE DATE: Friday, October 16, 2009

NEW DELIVERABLE PER CONTRACT:

1) 98 Pfizer Inc. ("PFE") Common Shares

2) Cash in lieu of .5 fractional PFE Shares*

3) \$3,300.00 Cash (\$33.00 x 100)*

* The cash portion of the deliverable remains permanently fixed as part of the option deliverable, and does not vary with price changes of securities also

included in the deliverable

APPLICABLE CONTRACT MONTHS: October, November, December 2009 and March 2010

SETTLEMENT PRICES AND POSITIONS: The underlying price for the WYE2C Futures contract deliverable, expressed in term of current market value,

would be calculated as follows:

WYE2C = .98 (PFE) + cash in lieu of .5 PFE shares

+\$33.00

Please note that the valuation would apply only to the WYE2C deliverable in terms of current market value of the deliverable securities. The resulting price would <u>not</u> be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends,

and other factors.

NOTES: The forecasted effect of the upcoming corporate event

on each clearing firms' positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report

(ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).

If you have any questions regarding the information provided in the document, please call CME Clearing risk management hotline at (312) 648-3888.